Actuate Announces Upcoming Presentation On Initial Data On Elraglusib In Combination With FOLFIRINOX At The AACR Special Conference On Advances In Pancreatic Cancer Research
Portfolio Pulse from Benzinga Newsdesk
Actuate Therapeutics announced promising initial data on the combination of Elraglusib with FOLFIRINOX and Losartan for treating metastatic pancreatic cancer. The data, presented at the AACR conference, showed deep, durable responses in patients, highlighting the potential of this combination therapy.
September 16, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actuate Therapeutics presented initial data showing promising results for Elraglusib in combination with FOLFIRINOX and Losartan in treating metastatic pancreatic cancer. The data suggests potential for overcoming chemoresistance and achieving deep responses in patients.
The presentation of promising initial data at a major cancer research conference is likely to positively impact Actuate's stock price. The data suggests potential efficacy in a difficult-to-treat cancer, which could lead to increased investor interest and confidence in the company's pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100